Montana’s new “right to try” law can’t come soon enough for some

Summary

Montana's expanded 'right to try' law aims to provide access to unapproved drugs after phase I trials. A father, Kris DeVault, seeks an experimental drug for his son Brody's rare condition, facing hurdles with FDA regulations and the drug's development timeline. Experts caution about the lack of proven safety and efficacy in early-stage trials.

Key Takeaways

1. Montana's new 'right to try' law theoretically expands access to experimental drugs that have completed phase I clinical trials, even for non-terminally ill patients.
2. Kris DeVault is seeking an experimental drug for his son Brody, who has creatine transporter deficiency, a rare condition with no cure.
3. Experts caution that phase I clinical trials do not prove a drug's safety or efficacy, raising concerns about patient access to unproven treatments.

Statement Breakdown

• Claimed Facts: 50% of statements the article presents as facts
• Opinions: 30% of statements classified as editorial or subjective
• Claims: 20% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article presents a balanced view by including expert opinions and acknowledging potential risks alongside patient desires. It relies on interviews and expert commentary, but the core claims about the law's existence and purpose are verifiable.

Bias assessment: Patient Advocacy Framing. The article prioritizes the emotional narrative of a parent seeking treatment for their child, framing the 'right to try' law as a potential lifeline. While acknowledging counterarguments, the overall tone leans towards highlighting the urgency and perceived benefits for patients.

Note: This article focuses on a parent's urgent need for experimental treatment, balanced by expert warnings about safety and efficacy. Consider the potential risks alongside the described benefits.

Credibility flag: Patient-centric, expert caution

Claimed Facts (9)

• This is a factual statement about Brody's diagnosis.
• This is presented as a factual statement about the medical reality of Brody's condition.
• This states the existence of a company and its work on a drug.
• This describes the specific action of a company and its product.
• This details the completion of a specific clinical trial.
• This states the historical existence of a law in Montana.
• This describes a legislative change and its conditions.
• This states the purpose of another law.
• This states the establishment of a specific board.

Opinions (5)

• This is a personal expression of hope and desperation from the father.
• This expresses a personal concern and fear about future developmental stages.
• This reflects the CEO's personal assessment and concerns regarding regulatory bodies.
• This is a rhetorical argument expressing a personal belief about autonomy and choice.
• This indicates DeVault's disagreement with the expert opinions presented.

Claims (6)

• While stated as a fact, this is an acknowledgment of uncertainty about an unproven treatment, bordering on a speculative claim about potential outcomes.
• This is a factual statement about the drug's testing history, but it implies a significant risk for patients like Brody, making the potential use of the drug dubious.
• This statement, while presented as fact, highlights regulatory non-compliance which raises questions about the drug's readiness and safety for any form of access, making its potential use dubious.
• This is a generalized statement about scientific caution, lacking specific evidence or examples within the article, making it a broad and potentially unsubstantiated claim.
• This statement, while likely true, is presented as a broad warning without specific context or evidence of such caution being universally applied or heeded in this specific instance, making it a generalized cautionary claim.
• This statement, while a reasonable opinion, is presented as an absolute truth by an expert, framing the current situation as inherently unfair without fully exploring the nuances of patient autonomy and risk assessment.

Key Sources

• Kris DeVault — Parent of Brody
• Ceres Brain Therapeutics — Biotechnology Company
• Thomas Joudinaud — CEO of Ceres Brain Therapeutics
• Aaron Kesselheim — Professor of Medicine at Harvard Medical School
• Montana Department of Health and Human Services — State Government Agency